LEGISLATIVE BEAT

Clinical Trials: State-of-the-Art Care Today, New Hope for Tomorrow

1414 Prince Street, Suite 204, Alexandria, VA 22314(703) 548-1225 • www.FightColorectalCancer.org

Amy Sears knew about clinical trials because, as a software engineer at the Minnesota Mayo Clinic, she had tested computer programs for collecting clinical trial data. But as a 34-year-old mother of two young children, she certainly didn’t expect to need a cancer trial. However, one Monday at work she had severe abdominal pain. Exactly one week later she was in surgery for colon cancer.  

“I thought it was the end of my life,” she remembers. Like Amy, most newly diagnosed patients are overwhelmed with fear and not ready to think about a clinical trial to improve treatments for future patients. They just want the best possible care to help save their lives. 

That’s exactly why Dr. Rocky Morton, a community oncologist in Des Moines, Iowa, considers clinical trials for most of his patients at the time of diagnosis.

“I believe that patients in clinical trials can truly get better care,” he says. “If the doctor and patient are involved in a trial, it ramps up the care.”  

“Many people think that in a clinical trial, some patients just get a ‘placebo’ (no real treatment) while others get the ‘real’ treatment,” adds Kate Murphy, C3’s Director of Research Communication and herself a 25-year

continued on page 6

VOLUME 3, ISSUE 4 SUMMER 2008

FROM THE PRESIDENT’S DESK ........................2

PREVENTION Screening Saves Lives ...................3

POLICY Meet Catherine Knowles ..............4

ADVOCATES IN ACTION ................5

C3 thanks Genentech BioOncology for an unrestricted charitable grant which made this issue of Momentum possible. C3 is solely responsible for newsletter content.

Moving towards better care and a cure

C3: MomentumC3: MomentumVOLUME 5, ISSUE 1 WINTER 2010Winning the fight against colorectal cancer

IN THIS ISSUE

By Mary Mitiguy Miller

They’ve been called the unsung heroes of modern medicine--those who voluntarily join clinical trials testing new treatments or procedures.  

Most people assume that these heroes volunteer for clinical trials only because they have very advanced cancer that hasn’t responded to any other treatments.

Not true. Amy Sears, for example, had undergone successful surgery for colon cancer and was starting six months of chemotherapy to further decrease the chance of recurrence when she agreed to join a clinical trial.  

In fact, clinical trials can be an option for people at all stages of disease or health.  Of the more than 250 colorectal cancer trials currently underway in the U.S., many are testing ways to prevent or detect very early cancer. One trial is testing a vaccine that would recognize precancerous protein in polyps and trigger the person’s immune system to destroy the polyps before cancer develops. Another trial is comparing different imaging techniques to find which tests (and frequency of tests) best detect new or recurrent cancer.  

Yet many trials are delayed or even cancelled because researchers can’t find enough participants. Only 3 to 5% of cancer patients participate in trials.

Jessica Mitchell (left), oncology nurse practitioner at the Mayo Clinic made sure that patient Amy Sears (right) had all the information needed before deciding to join a clinical trial.

PHO

TO B

Y JO

E K

AN

E, M

AYO

CLI

NIC

www.FightColorectalCancer.org2

Although C3 is still considered a young organization (we’ll be starting our fifth year in March), our friends and advocates feel like old, dear friends to us. And as we finish off 2009, it’s nice to remember all that we’ve been through together.

We’ve marched on Congress, we’ve flooded the phone lines to the Capitol, we’ve put new research dollars toward beating late-stage colorectal cancer and we’ve held companies and government agencies accountable to patients.

C3 is changing the landscape for colorectal cancer patients. We are able to do this because of the support we receive from you, our friends. Thank you for all that you have done to forward the colorectal cancer cause, and all that you have done to help C3 become the organization it is today.

In the past six months, we said goodbye to Joe Arite, C3’s Policy Director since 2007, who left the organization to follow his heart to Chicago. We were thrilled to find a wonderful addition and perfect fit in Catherine Knowles, C3’s new Director of Policy (page 4).

We provided another young researcher the opportunity to make a difference in colorectal cancer by awarding our second Lisa Fund Research grant to Dr. Jeffrey Chou, who is studying colorectal cancer stem cells. The search for the third Lisa Fund Research grant recipient is underway right now, and will be announced next spring. One hundred percent of the grant funding came from C3 donors,

FROM THE PRESIDENT’S DESK

Board of DirectorsNancy Roach, Board Chair

Alan Balch, Ph.D., Vice Chair

Steven Depp, Ph.D., Treasurer

Robert Erwin, Board Secretary

Carlea Bauman, President

Gordon Cole

Medical Review NetworkNancy Baxter, MD, FRCSC University of Toronto

Al B. Benson III, MD, FACP Northwestern University

Richard Goldberg, MD University of North Carolina

Axel Grothey, MD Mayo Clinic College of Medicine

Heinz-Josef Lenz, MD, FACP University of Southern California

John Marshall, MD Georgetown University Medical Center

Howard McLeod, PharmD University of North Carolina

Neal Meropol, MD Fox Chase Cancer Center

Edith Mitchell, MD Thomas Jefferson University

Daniel Sargent, Ph.D. Mayo Clinic College of Medicine

Joel Tepper, MD University of North Carolina

Thanks for a Year of Friendships and Successes By Carlea Bauman President

and 100 percent of it went directly to Dr. Chou. By the end of 2010, C3 will have committed nearly $100,000 to research for late stage colorectal cancer (www.FightColorectalCancer.org/LisaFund).

We’re looking forward to seeing old friends and making new ones at the 2010 Call-on Congress in March (page 5 and back cover). We hope that anyone touched by colorectal cancer in any way – as a patient, caregiver, family member, friend or medical professional – will come to Washington, DC to have their voices heard. Our empowering and inspiring event has had a major impact on colorectal cancer legislation and research funding.

On a personal note, I am thrilled to announce that in August, my husband and I adopted a baby girl. I took some time off in the fall to spend with our new daughter — time that I cherished immensely. The C3 staff and Board of Directors didn’t skip a beat while I was knee deep in formula and diapers for three months. They have my unending gratitude for picking up the extra work with humor, grace and overwhelming generosity. I returned to work full time in November.

So, please join us as we celebrate our successes, which could not have been achieved without your support and generosity. We also remember those who have lost their fight and in their memory we will work even harder.

May you all have a wonderful holiday season and a happy new year.

2009 Annual ReportTo obtain a copy of C3’s 2009 Annual Report contact Jerri Lyn Mooney at

1-703-548-1225 x10 or you can download a copy at http://link.FightCRC.org/ 09AnnualReport.

2009 ANNUAL REPORT

C3 Momentum Winter 2010 3

LEGISLATIVE BEATPREVENTION

Screening Saves Lives: Do ItBy Carlene Canton

The facts are clear: screening for colorectal cancer saves lives by detecting the cancer at early stages when it can be successfully treated. Even better: screening prevents colorectal cancer by detecting and removing the polyps that can turn into cancer.

President Obama said as much in his speech before the joint session of Congress in September,

“...There’s no reason we shouldn’t be catching diseases like breast cancer and colon cancer before they get worse. That makes sense, it saves money, and it saves lives.”

Eric Vogt, 67, is one colorectal cancer patient who is glad the word is finally getting out. He offers his own story as a case in point. He firmly believes that a colonoscopy in 2008 that found stage III colon cancer saved his life. He only wishes he had gotten a colonoscopy ten years earlier.

Eric’s is a cautionary tale. He offers words of warning to people over the age of 60 who a decade or more ago may have initially been told that a flexible sigmoidoscopy (flex sig) once every ten years was all they needed to protect themselves from colon cancer. “A flex sig only looks at the first 18 inches of the colon. A colonoscopy looks at the entire colon, and will find polyps or cancer beyond the reach of the flex sig.”

When he turned 50, Eric wanted to get a colonoscopy, because his brother’s colonoscopy had revealed polyps. But his insurer didn’t cover colonoscopy as a routine screening tool and he had a flex sig screening instead.

Fifteen years later, after he turned 65, he had a Medicare-covered colonoscopy. That’s when he found

that he had stage III colon cancer located on the right side of his colon, beyond the reach of the flex sig.

His doctors told him the cancer was slow-growing, and had it been discovered 10 to 15 years earlier, it could have been easily removed – maybe even at the polyp stage. In that case, he likely would never have developed colon cancer at all.

Eric was no stranger to the earth-shattering news of a cancer diagnosis. Six years ago, at age 61, he was diagnosed with stage III multiple myeloma.

Eric spent three years in rigorous treatment for myeloma, a cancer he believes he contracted after decades of firefighting, in which he was exposed to toxins and pesticides, including Agent Orange. His multiple myeloma has been in remission since 2004.

But the retired firefighter is not one to look back. Instead, he looks forward: to remission, to future screenings and to spreading the word to his family and friends that colorectal cancer screening saves lives.

It wasn’t all that long ago that people didn’t discuss breast cancer in polite

Eric Vogt cherishes time with his grandchildren.

Screening RecommendationsIn a perfect world everyone who needs a screening colonoscopy would be able to get one, covered by insurance and performed by a highly experienced medical team. We are not there yet.

“Any screening is preferable to no screening,” says Dr. Heinz-Josef Lenz, Professor of Medicine in the University of Southern California (USC) Departments of Medicine and Preventive Medicine, and Co-Director of the Colorectal Center at the USC/Norris Comprehensive Cancer Center.

While “colonoscopies are the gold standard of screening,” says Dr Lenz, there are alternative screening methods available. The United States Preventive Services Task Force recommends the following minimum screening schedule for adults 50 to 75 years of age: (1) a screening colonoscopy every ten years, (2) a sigmoidoscopy every five years with high-sensitivity stool tests every three years or (3) a high-sensitivity stool test for hidden blood done yearly.

Family history or any positive test results may require a different screening schedule.

To read more, check the United States Preventive Services Task Force screening recommendations at http://link.FightCRC.org/crcscreen.

society, and many to this day are uncomfortable mentioning colon, rectal, or anal cancer out loud. As a true believer that screening saves lives, Eric isn’t shy talking about colorectal cancer. “A lot of people don’t want to talk about colon cancer and, as a result, people could have a family history of it without even being aware of it,” he said.

That was the case in his own family. He learned that an uncle and a cousin both had advanced colorectal

continued on page 7

www.FightColorectalCancer.org4

POLICY & ADVOCACY

New C3 Policy Director: Not a New Kid in TownBy Mary Mitiguy Miller

C3’s new Director of Policy, Catherine Knowles, will be on familiar ground as she directs advocates through the halls of Congress and monitors legislation that impacts colorectal cancer patients. After she graduated from law school, Catherine spent five years working on Capitol Hill before joining C3 in September.

In her former role as legislative counsel for Rep. Kay Granger (R-TX), Catherine was in the thick of health care issues facing Congress. Rep. Granger sits on the Appropriations Committee which funds the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC), and also leads several health-related initiatives such as the Congressional Prevention Caucus.

Rep. Granger lost her father to colorectal cancer, and has made colorectal cancer one of her top priorities. She first introduced the Colorectal Cancer Prevention, Early Detection, and Treatment Act (H.R. 1189) in July 2006, and a part of Catherine’s job was to keep the bill moving forward. H.R. 1189 will create a national colorectal cancer screening program, making this lifesaving measure available to poor, uninsured and underinsured Americans.

Because H.R. 1189 is also one of C3’s top priorities, Catherine had worked closely with Joe Arite, C3’s former Director of Policy, to increase support for the legislation. When Joe relocated to Chicago in September 2009, Catherine saw it as a perfect opportunity to join C3 where she could apply her years of experience with political and regulatory processes to focus on just one issue: colorectal cancer.

Catherine was already impressed with C3’s advocates, having heard

from other legislative staffers how they brought their personal stories to Capitol Hill during Call-on Congress and stood out (in their resplendent Cover Your Butt T-shirts) from the usual daily blur of lobbyists and visitors.

“Legislators are so impressed by constituents who use their vacation time and their own money to come all the way to Washington,” she said. “Their passion and personal stories have a far greater impact than lobbyists paid to cruise the halls of Congress.”

This March, it will be Catherine training and escorting C3 advocates to visit elected officials to tell their stories as part of 2010 Call-on Congress on March 15-18. “I’m looking forward to working with advocates from across the country to get H.R. 1189 passed this session,” she says.

As a graduate of Indiana University Law School, Catherine has also worked at the Federal Communications Commission and the National Telecommunications & Information Administration. Her

familiarity with the inside workings of regulatory agencies will come in handy at C3, where part of her job is to monitor issues affecting colorectal cancer patients at federal agencies such as the Food and Drug Administration.

Catherine blogs and posts political Action Alerts frequently on C3’s website. She holds monthly meetings with the Grassroots Action Committee, plus quarterly conference calls with C3 advocates all over the country. She is available by phone or email if people want advice about local, state or federal political action. She can be reached by telephone at 1-703-548-1225 x12 or by email at Catherine.Knowles@FightColorectalCancer.org.

“C3 has an outstanding reputation as a group that has accomplished a tremendous amount in a short period of time,” Catherine said. “It is an honor to be part of a group that not only pays attention to the science of colorectal cancer, but also knows how to rally the troops and impact change.”

Catherine Knowles, C3 Director of Policy

Call-on CongressWhat: Two-plus days that include training, networking and visiting Congress

When: March 15–18, 2010

Who: Patients, caregivers, family, friends and medical professionals

Cost: $150 plus travel and lodging

Deadline: Application deadline is Feb. 1, 2010

To register, visit http://link.FightCRC.org/ConC2010

C3 Momentum Winter 2010 5

POLICY & ADVOCACY

Advocates in Action: Meet Pam SeijoBy Carlene Canton

C3’s newest vice chair of the Grassroots Action Committee is Pam Seijo, an author, former teacher, mother of two and resident of West Virginia. Pam takes over the reins of this advocacy committee from outgoing vice chair Marilia Sardinha. Momentum readers will be hearing from Pam in future issues. Here is her story.

Faith. Hope. Inspiration. Great words for anyone to live by. But for Pam Seijo these have been words to cling to since her long journey with colorectal cancer began.

She had been in pain for some time. Finally, one early morning in August of 2000, the pain was so severe that she rushed to the emergency room. There she learned that her colon had ruptured due to a very large rectal tumor that had broken through the colon wall.

Her body was in so much stress that doctors had to stabilize her before even attempting surgery. Once in surgery they discovered the tumor was far too large to remove and did their best to repair the colon and performed a temporary colostomy.

Pam spent four days in and out of consciousness after surgery and then began six weeks of chemotherapy and 34 radiation treatments, all aimed at shrinking the tumor so that it could be removed.

At the end of that ordeal she got the heartbreaking news that the tumor had actually grown in size and remained inoperable. Her doctors were out of ideas.

That’s when Pam added “determination” to her list of words. After much searching she located a surgeon at the University of Virginia who felt that while the tumor seemed inoperable, the benefits of surgery outweighed the risks.

On Dec. 27, 2000 Pam received what she described as “the best Christmas gift ever” when her doctor, an oncology colorectal surgeon, along with a gynecological oncologist and a urologist performed an eight-hour surgery. What they had discovered days prior to the surgery was sobering to anyone in the oncology field. Pam’s tumor had attached itself to the uterus, to the vaginal wall, and to the bottom of the spinal column. The surgeons repositioned the bladder, performed a complete hysterectomy, removed the tumor, the rectum and most of the colon and made that temporary colostomy permanent.

The need for aggressive treatment didn’t end there. More chemotherapy continued over the next 18 months during which Pam felt sick much of the time, suffering from hand-foot syndrome, diarrhea and a long list of other complications.

Eventually the doctors decided to put her on a long-term, low-dose of Xeloda® (capecitabine) which she will continue for the rest of her life.

While she is proud of surviving this aggressive cancer and treatment, Pam is equally proud of the fact that she

Join Pam Seijo for C3’s 2010 Call-on Congress

As one of her primary goals this year,

Pam wants to increase state-by-state

participation in the 2010 Call-on

Congress. “We had advocates from 17

states and Washington, D.C. in 2009 and

I want to boost that for the 2010 event.”

Each year C3 advocates spend a day in

training and then head up to Capitol

Hill to “Call-on Congress.” C3 sets up

meetings so that the advocates can talk

with their elected officials to push for

issues like a national screening program

and increased funding for colorectal

cancer research. The next Call-on

Congress is set for March 15-18, 2010.

It’s a powerful experience, Pam said.

“I’ve seen people attend a Call-on

Congress training session scared and

intimidated by the thought of visiting

Congress. By the time they leave, they

are able to raise their voices effectively,

and have made great friends.”

States with Call-on Congress

participants in 2009 are listed below.

If your state is not represented, you

can make a difference by meeting with

your elected officials. If your state is

listed, join the team! The deadline for

registration for 2010 Call-on Congress is

February 1, 2010.

States with Call-on Congress

participants in 2009 included: Alabama,

Arizona, California, Florida, Maine,

Maryland, Minnesota, New Hampshire,

New Jersey, New York, North Carolina,

Ohio, Oregon, Pennsylvania, Texas,

Virginia, Washington, D.C., West Virginia.continued on page 7

Pam Seijo, Grassroots Action Committee Vice Chair

www.FightColorectalCancer.org6

MEDICAL

continued from page 1

Clinical Trials: State-of-the-Art Care Today, New Hope for Tomorrow

survivor of both breast and colon cancer. “That’s not true. All patients get state-of–the-art treatment, plus some get an additional experimental intervention.”  

In Amy’s case, her surgery successfully removed all of the tumor in her colon. Medical oncologist Dr. Steven Alberts from the Mayo Clinic recommended six months of chemotherapy to decrease chances of recurrence. He also mentioned the possibility of a clinical trial testing a new medicine to ease the side effects of peripheral neuropathy (painful tingling in fingers and toes) common with her chemotherapy. 

Oncology nurse practitioner and study coordinator Jessica Mitchell “spent plenty of time, sitting down with me and going through all the information,” Amy said. When she was assigned to the group receiving standard chemotherapy plus the new experimental drug, she felt like it was no big deal. She said, “When I came in for chemo, they just hung another intravenous bag.” At each visit, she answered an extra questionnaire about side effects. Two years after her treatment, Amy remains cancer-free. 

Some clinical trials, Kate Murphy explains, can require extra tests or follow-up appointments. Your doctor will have more paperwork to track symptoms and data. “People will be watching you very carefully. You’ll be checked often for side effects, and someone has already thought hard about different ways to respond to those side effects.”  

Both Kate and Dr. Morton serve on national committees overseeing the design and progress of clinical trials all over the United States, and Kate says it’s important for people to remember that an independent committee monitors the health of patients at

all trial sites. If patients aren’t being helped by the trial, the monitoring committee can stop the trial early.

Equally as important, she adds, is that patients can resign from a trial at any time, for any reason.

People often believe they must live near a university or major medical center to participate in clinical trials. Not so, says Dr. Morton, who is nationally known for his work at moving research findings quickly into community practice. Local oncologists conduct clinical trials in the patient’s own community and provide ongoing care if the patient chooses a trial in a distant site. “We have more than 100 clinical trials going on in our area alone. Virtually everyone in Iowa lives within 30 miles of a community oncologist who can participate in trials.” 

Clinical trials benefit both patients and their local doctors, he adds. “Clinical trials give us the ability to provide our patients some of the latest care that otherwise they wouldn’t get unless they traveled to a cancer

center.” Research results are also more meaningful when the research includes people of diverse backgrounds from all over the country.

For Amy, the clinical trial was just an added part of her care. “I think it’s well worthwhile for patients to consider it for themselves—and for the education and research of cancer,”  she said. 

“Every little bit helps to advance to the next cure or helpful remedy.”   

RESOURCES

• Call C3’s Answer Line (1-877-4CRC-111) for information and/or referral to a clinical trial-matching service

• Keep up with Kate Murphy’s updates on research and trials at www.FightColorectalCancer.org/research_news

• Learn more about clinical trials at www.Cancer.gov/ClinicalTrials/learning

QUESTIONS TO ASK

As a long-time survivor, as well as a research and patient advocate, C3’s Kate Murphy suggests the following specific questions:

• When choosing a cancer specialist, ask: “Does this office offer clinical trials? If not, would the doctor be willing to participate if I join a trial that could be done locally?”

• When considering treatment options, ask: “What trials are available for my stage of disease?”

• If considering a specific trial, be sure the trial’s goals work with your own goal. Small Phase I trials have very different goals than large, national Phase III trials.

• Clarify what a trial requires (tests, appointments) compared to standard treatment.

• Who pays? Medicare and many insurances pay for ‘customary treatment,’ with the trial covering extra care or experimental medicines. But that’s not always true, especially for Phase I trials. Check ahead.

C3 Momentum Winter 2010 7

Steve Baker • Ted Blau • Joe Casone • Nancy Crafts • Janet Crane • Edmond Dowe • Lisa Dubow • Avi Elbachri

Anthony Evans • Fran Hagin • Arlene Hartill • Ian Harvey • Bill Keane • Rae Ann Littler • Joan Maddox • Patricia Ann Martins

Kevin May • David Moskal • Christine Niemi • Patricia Pagliaro • Henrietta Ryder • Christine Teepe • Kenneth Weiner

WE HONOR AND REMEMBER

C3’s Work Honors and Remembers Our Loved OnesC3 receives donations that honor the work and the lives of patients and advocates fighting colorectal cancer.

We also receive donations in memory of people who have lost their battle with colorectal cancer, and whose family and friends chose to remember them and their courage through a donation to C3.

Following are the names of people who have been honored or memorialized by donors between April and October 2009.

Donations include support for C3’s Lisa Fund, which directly funds research. Visit www.FightColorectalCancer.org/LisaFund for more information.

For information about honoring or remembering a loved one, contact Ben Basloe, Director of Development at Ben.Basloe@FightColorectalCancer.org or by phone at 1-703-548-1225 x17.

Donations to C3 can go farther when corporate matching funds are available. Ask Ben for more information.

cancer years before—which would have strengthened his case for getting an earlier colonoscopy. He believes screening has saved all of his siblings. All had colonoscopies and as a result some had early polyps removed. None has developed colon cancer.

As a result, he shares his story every day of his life.

“I talk about colon cancer to everyone.

I don’t think there’s a single person who knows me who doesn’t know my experience with it,” he said. He talks to family, to friends and to fellow members at Rotary meetings. “I’ll just get up and ask: ‘how many of you have had your colonoscopy?’ I just tell them to save themselves some pain and anguish and get it done.

“How can we not do something that we know saves lives?”

Today, with both his colorectal cancer and multiple myeloma under control or in remission, Eric Vogt is retired and enjoying his life in southern California with his two sons and six grandchildren nearby.

When he thinks about how much he almost lost he comes to only one conclusion.

“Colonoscopies save lives. Get one.”

Screening Saves Lives. Do It.continued from page 3

Advocates in Action: Meet Pam Seijocontinued from page 5

never stopped being a mom to her two children who were 11 and 13 at the time of her diagnosis.

“I just made the choice to keep going,” she said. “When I was nauseous, I attended my son’s games with a bucket in hand. I did not miss my daughter’s cheerleading events and competitions, or her ballet or tap recitals. I didn’t feel great but I figured as long as I was still here I was going

to make it to the events that are such a part of their childhood.”

Along the way, Pam became a published author, transforming a daily journal into a book published in 2003: A Mirrored Image: A Story About Cancer and Survival.

“I believe the reason I was diagnosed with cancer and survived is to share my story and share a message about hope,” she said.

A Cherished YearOutgoing vice chair of C3’s Grassroots Action Committee Marilia Sardinha offers a few words about what the past year has meant to her:

“C3 has made a significant impact in my life. I have made lifelong friendships with other advocates, shared my story and have tried to make a difference along the way. My relationship with C3 is a gift that I cherish.”

Readers can meet Marilia and Pam and other advocates at C3’s 2010 Call-on Congress in March.

italics indicate memorial donations

www.FightColorectalCancer.org8

1414 Prince Street Suite 204 Alexandria, VA 22314

Register to receive future issues of Momentum atwww.FightColorectalCancer.org

To make corrections to your contact information or to remove your name from the mailing list, please email info@FightColorectalCancer.org or call 1-703-548-1225.

NONPROFITU.S. POSTAGE

PAIDSTAMFORD, CT

PERMIT NO. 102

CALL-ON CONGRESS REGISTRATION NOW OPEN

“�Change�doesn’t�come�from�Washington.��Change�comes�to�Washington.”�

President Barack Obama

Imagine yourself in the Halls of Congress...fighting for an end to colorectal cancer. You CAN do it, and we are here to help.

C3 is proud to bring advocates together from around the country to participate in our fourth annual training program and colorectal cancer advocacy day. We invite you to register to join us and let your voice be heard.

This is your chance to meet fellow colorectal cancer advocates, develop the skills you need to be a great advocate back home, and learn what Congress’ role is in fighting this terrible disease. Most important, you’ll conclude your visit by putting what you learn into practice on Capitol Hill in meetings with your Members of Congress and their staff. We�will�provide�you�with�the�tools�and�training�you�need�to�be�a�successful�advocate,�so�that�your�voice�can�bring�change�to�Washington!

http://link.FightCRC.org/ConC2010

March 15-18, 2010

C3 Board Member Gordon Cole (right)with Rep. Howard Coble, (R-NC) at the 2009 Call-on Congress.